title: A comparative study on the cost of new antibiotics and drugs of other therapeutic categories.
abstract: BACKGROUND
  Drug treatment is becoming more expensive due to the increased cost for the introduction of new drugs, and there seems to be an uneven distribution of medication cost for different therapeutic categories. We hypothesized that the cost of new antimicrobial agents may differ from that of other therapeutic categories and this may play a role in the stagnation of development of new antibiotics.
  
  
  RESULTS
  We performed a pharmaco-economical comparative analysis of the drug cost of treatment for new agents introduced in the United States drug market in various therapeutic categories. We calculated the drug cost (in US dollars) of a ten-day treatment of all new drugs approved by the FDA during the period between January 1997 and July 2003, according to the 2004 Red Book Pharmacy's Fundamental Reference. New anti-neoplastic agents were found to be the most expensive drugs in comparison to all other therapeutic categories, with a median ten-day drug-treatment cost of US$848 compared to the median ten-day drug-treatment costs of all other categories ranging from US$29 to US$301. On the other hand, new antimicrobial drugs were found to be much less expensive, with a median ten-day drug-treatment cost of US$137 and $US85 for all anti-microbial agents and for anti-microbial agents excluding anti-HIV medications, respectively.
  
  
  CONCLUSIONS
  The drug-treatment cost of new medications varies considerably by different therapeutic categories. This fact may influence industry decisions regarding the development of new drugs and may play a role in the shortage of new antimicrobial agents in the fight against the serious problem of antimicrobial resistance.
authors.affiliation: Alfa Institute of Biomedical Sciences, Athens, Greece; Department of Medicine, "Henry Dunant" Hospital, Athens, Greece; Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts, United States of America. matthew.falagas@tufts.edu
authors.forename: Matthew E
authors.initials: ME
authors.lastname: Falagas
authors.forename: Konstantinos N
authors.initials: KN
authors.lastname: Fragoulis
authors.forename: Ioannis
authors.initials: I
authors.lastname: Karydis
mesh_terms: D000900:Anti-Bacterial Agents / Q000191:economics*; D000970:Antineoplastic Agents / Q000191:economics; D017277:Drug Approval / Q000191:economics; D016527:Drug Costs; D055808:Drug Discovery / Q000191:economics; D006801:Humans; D004364:Pharmaceutical Preparations / Q000191:economics*; D014481:United States
chemical_list: D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D004364:Pharmaceutical Preparations